Day: November 25, 2021

In 2022, SNOMED International will extend the core of SNOMED CT’s structured clinical terminology to deliver an open, standalone sub-ontology to support the scope of content within the International Patient Summary (IPS) under a Creative Commons license.

London, United Kingdom, Nov. 25, 2021 (GLOBE NEWSWIRE) — At SNOMED International’s recent October Business Meetings held in London, the organization’s governance bodies enacted a decision to extend the core of SNOMED CT’s structured clinical terminology to deliver an open, standalone sub-ontology to support the scope of content within the International Patient Summary (IPS.)

The IPS is an electronic health record extract containing essential healthcare information for use in the unscheduled, cross-border care scenario, as well as for local, regional and other care scenarios. It is a minimal, non-exhaustive set of data elements defined by ISO/EN 17269 and delivered by HL7 in both CDA and FHIR using a curated set of SNOMED CT terms.

There is a groundswell of support across all health sectors to increase the portability and usability of patient information for the purpose of safe health care delivery. In 2019, SNOMED International and HL7 International announced the formalization of a license agreement in which a relevant ‘Free for Use’ Set of SNOMED CT coded concepts would be used within the HL7 IPS. Most recently, we watched as G7 leaders collaborated to release a communique on the dire need to progress a global health interoperability agenda. IBM offers a working definition of interoperability as “the timely and secure access, integration and use of electronic health data so that it can be used to optimize health outcomes for individuals and populations.”  The G7 communique, which highlighted the importance of enabling digital healthcare systems worldwide to work together seamlessly as patients move between providers, facilities and even countries, is an impactful statement that rippled throughout the global health community. A charge taken up by the Global Digital Health Partnership, it is one SNOMED International is eager to support.

Embracing a collaborative approach, “SNOMED International has been pleased to continue to work with HL7 International and partners across Europe and beyond to define SNOMED CT content for use in the International Patient Summary,” offered SNOMED International Management Board Chair, Joanne Burns.

Continuing to act in the spirit of the IPS Freeset, SNOMED International has committed to create and release an openly available IPS sub-ontology in the first half of 2022 to enhance the existing cross border movement of information, and ultimately health system interoperability. Unlike SNOMED International’s Global Patient Set, a flat list of SNOMED CT codes and terms, an IPS sub-ontology will provide implementers with a product that can be used in healthcare solutions using the power of SNOMED CT through its query language and hierarchies for the specified scope. Use of the IPS sub-ontology will allow for more effective use of clinical data analytics and decision support, and for Artificial Intelligence applications.

Alex Elias, Chair of SNOMED International’s General Assembly, the organization’s Member governance body, has observed a significant increase in discussion regarding the IPS. “2021 has seen increased interest by governments and Health and Care organizations globally for implementing the IPS to enhance timely cross border health information flow and interoperability. This has been a primary driver in SNOMED International supporting this recent initiative to make the IPS sub-ontology openly available with SNOMED CT content.“

An organization with an extensive history and active program of collaboration, SNOMED International CEO, Don Sweete, has played a pivotal role in positioning the IPS sub-ontology as a ‘soon to be achieved’ reality. “As the G7 Health Ministers recently indicated, the importance of enabling digital healthcare systems worldwide to work together seamlessly so patients don’t suffer as they move between providers, facilities and even countries is a sentiment that has rippled throughout the global health community”, offered Sweete. He went on to state that, “continued work with fellow health standards development, national, clinical and technical entities, SNOMED International will dedicate resources to achieve the goal of digital health interoperability.” Sweete added, “equipping the IPS, already one of the best examples of international collaboration among standards bodies, with the full capability of SNOMED CT’s ontological design is a significant action that we can contribute to achieving health information access gains for patients.”

Over the coming months, SNOMED International is formalizing the steps and due diligence required to make the IPS sub-ontology available for broad release. Throughout this period, SNOMED International will continue to define the IPS sub-ontology, from content through to its release and maintenance approach for launch in the first half of 2022.

Visit SNOMED International’s IPS Sub-Ontology information page or subscribe to the organization’s news service to learn more as this initiative progresses. For additional information, contact info@snomed.org.

About SNOMED International

SNOMED International is a not-for-profit organization that owns and develops SNOMED CT, the world’s most comprehensive healthcare terminology product. We play an essential role in improving the health of humankind by determining standards for a codified language that represents groups of clinical terms. This enables healthcare information to be exchanged globally for the benefit of patients and other stakeholders. We are committed to the rigorous evolution of our products and services, to deliver continuous innovation for the global healthcare community. SNOMED International is the trading name of the International Health Terminology Standards Development Organisation.

www.snomed.org

Attachment

• SNOMED CT: The global language of healthcare

Kelly Kuru
SNOMED International
comms@snomed.org

دبي الامارات العربية المتحدة25 نوفمبر / تشرين ثاني 2021/PRNewswire/ —
أعلن كل من نادي الجزيرة الإماراتي الحائز على بطولة دوري أدنوك للمحترفين 2020-2021، وشركة ألفكسو للوساطة المالية، عن توقيع اتفاقية شراكة تجارية هي الأولى من نوعها في المنطقة بشكل عام، لتصبح ألفكسو شريك رسمي للإستثمار لفريق كرة القدم الأول بنادي الجزيرة ابتداءً من الموسم الحالي 2021-2022، حتى نهاية موسم 2022-2023.

تعتبر هذه الشراكة التاريخية نواة العمل الطموح والجاد من المسؤولين في كلا الطرفين من مشاركة رؤيتهم وأهدافهم مع عملائهم وجماهيرهم في جميع أنحاء الخليج العربي والشرق الأوسط، حيث سيسلط هذا التحالف الضوء على أهمية التفاني في تطوير المهارات اللازمة للنجاح على أرض الملعب وكذلك في عالم الاستثمار.

تأسس نادي الجزيرة عام 1974 بعد اندماج ناديي الخالدية والبطين، ويخوض فريق الكرة مبارياته على ملعب محمد بن زايد الذي يتسع لـ 38 ألف متفرج، وينافس نادي الجزيرة في دوري أدنوك للمحترفين، بالإضافة إلى مشاركته المنتظمة في دوري أبطال آسيا، وفاز بلقب الدوري في 2011، 2017، و2021 إضافة لكأس رئيس الدولة في 2011، 2012، و2017. كما يترقب الفريق حاليا مشاركته الثانية في كأس العالم للأندية في بداية العام المقبل، حيث شارك في نسخة 2017 وبلغ الدور نصف النهائي.

تأسست ألفكسو في عام 2014، وهي شركة وساطة مالية تهدف إلى تطوير مهارات التداول لدى المستثمرين في الأسواق المحلية والعالمية. وهي من الشركات التي تُلهم مستخدميها إلى التعلم والتداول في نفس الوقت، لإن القائمون عليها يؤمنون إيمانًا راسخًا بأن المعرفة العملية التطبيقية هي المفتاح الحاسم للنجاح.

تعليقًا على إتمام عقد الشراكة، قالت يائيل كلاينمان، العضو المنتدب لمجموعة VPR المالية الآمنة: “نحن متحمسون لتوسيع آفاق نجاحنا مع أحد أبرز الأندية في آسيا والخليج العربي من خلال توفير فرص استثنائية لعملائنا ولمشجعي نادي الجزيرة حتى يجمعوا بين الإلهام والطموح عبر هذه الشراكة. نحن ملتزمون بأن نحقق هدفنا لنصبح وسطيًا مألوفًا في الدول العربية، حتى نحصل على ولاء عملائنا على المدى الطويل. نحن نتطلع إلى إنجاح هذه الشراكة نجاحًا هائلاً”.

من جهته قال السيد علي يوسف الحمادي، المدير التنفيذي لمجموعة نادي الجزيرة “سعداء بهذه الشراكة المبتكرة والأولى من نوعها في المنطقة مع شركة ألفكسو للوساطة المالية، ورأينا أن أوجه التشابه بين النادي والشركة كبيرة وواضحة لأن الجزيرة وألفكسو يتقاسمان الطموح المتواصل للابتكار والتطور وتقديم الأفضل للجمهور والتواصل معهم بشكل مستمر لضمان حصولهم على أفضل الخدمات والتجارب الرقمية والواقعية أيضا. نحن على ثقة أن هذه الشراكة ستفتح آفاقا أرحب للطرفين وستكون بداية لتعاون أكبر وأشمل في المستقبل القريب بما يعود بالفائدة على النادي والشركة وعلى قاعدتهما الكبيرة من المشجعين والعملاء”.

وذكر السيد / إيريك إم غوتشالك، المدير التنفيذي لشركة إم إم سي سبورتز، الذي ساهم، بالتعاون مع شركة IMAC ميديا، في إكمال اتفاقية الشراكة بين الجزيرة والفكسو “تعتبر الشراكة بين نادي الجزيرة والفكسو علامة فارقة بالنسبة لكرة القدم الإماراتية، وللمرة الأولى في عالم التداول تقوم علامة تجارية حصرية مثل الفكسو بعقد شراكة مع نادي إماراتي.

اتصل: presse@alvexo.eu

Logo: https://mma.prnewswire.com/media/1696418/Alvexo_Logo.jpg

NEW YORK, Nov. 24, 2021 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of StoneCo Ltd. (NASDAQ: STNE) between March 11, 2021 and November 16, 2021, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 18, 2022.

SO WHAT: If you purchased Stone securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Stone class action, go to http://www.rosenlegal.com/cases-register-2203.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 18, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) StoneCo was experiencing difficulties in implementing its credit product; (2) StoneCo faced significant risks via its point-of-sale vendor, PAX Global Technology Ltd.; (3) as a result of the foregoing, the Company’s financial results would be adversely impacted; and (4) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Stone class action, go to http://www.rosenlegal.com/cases-register-2203.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com